Scholarlink

<p>Proliferative diabetic retinopathy (PDR) is the advanced stage of&#xa0;DR and characterized by retinal neovascularization (RNV). The diagnosis of PDR relies primarily on imaging features and blood glucose levels. Whether early biomarkers in other biofluid applied in the evaluation of PDR and RNV remain elusive. In total, 40 Chinese type-2 diabetes with DR and 21 non-diabetic subjects were recruited. Tear glycometabolic profiles and glycometabolite levels were comprehensively analyzed using both untargeted and targeted metabolomics approaches. Additionally, we employed multivariable logistic regression models, Pearson correlation analysis, receiver operating characteristic curve (ROC), retinal non-perfusion area detection and choroid sprouting assay to evaluate and validate the association between tear metabolites and PDR. Our metabolomic analysis revealed significantly elevated levels of metabolites related to the TCA cycle as well as D-glutamine and D-glutamate pathway in PDR subjects compared to non-diabetic controls. Among these metabolites, the fasting tear lactate was the highest in PDR subjects relative to other tear monosaccharides. Notably, tear lactate emerged as an independent risk factor for PDR, achieving an area under the curve (AUC) of 0.896 in predictive modeling. Furthermore, the tear lactate was validated to have effect on RNV. In summary, the study delineated glycometabolic features in tears of type-2 diabetes patients with PDR and identified tear lactate could be a promising novel marker for PDR evaluation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tear lactate improves the evaluation of proliferative diabetic retinopathy in type-2 diabetes patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月18日

查看全文
  • Xin Wen,
  • Tsz Kin Ng,
  • Guihua Zhang,
  • Haoyu Chen,
  • Zhenggen Wu,
  • Qingping Liu,
  • Mingzhi Zhang

摘要

Proliferative diabetic retinopathy (PDR) is the advanced stage of DR and characterized by retinal neovascularization (RNV). The diagnosis of PDR relies primarily on imaging features and blood glucose levels. Whether early biomarkers in other biofluid applied in the evaluation of PDR and RNV remain elusive. In total, 40 Chinese type-2 diabetes with DR and 21 non-diabetic subjects were recruited. Tear glycometabolic profiles and glycometabolite levels were comprehensively analyzed using both untargeted and targeted metabolomics approaches. Additionally, we employed multivariable logistic regression models, Pearson correlation analysis, receiver operating characteristic curve (ROC), retinal non-perfusion area detection and choroid sprouting assay to evaluate and validate the association between tear metabolites and PDR. Our metabolomic analysis revealed significantly elevated levels of metabolites related to the TCA cycle as well as D-glutamine and D-glutamate pathway in PDR subjects compared to non-diabetic controls. Among these metabolites, the fasting tear lactate was the highest in PDR subjects relative to other tear monosaccharides. Notably, tear lactate emerged as an independent risk factor for PDR, achieving an area under the curve (AUC) of 0.896 in predictive modeling. Furthermore, the tear lactate was validated to have effect on RNV. In summary, the study delineated glycometabolic features in tears of type-2 diabetes patients with PDR and identified tear lactate could be a promising novel marker for PDR evaluation.